- Home
- OLED vs BBIO Comparison
OLED vs BBIO Comparison
Compare OLED & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLED
- BBIO
- Stock Information
- Founded
- OLED 1985
- BBIO 2015
- Country
- OLED United States
- BBIO United States
- Employees
- OLED N/A
- BBIO N/A
- Industry
- OLED Semiconductors
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- OLED Technology
- BBIO Health Care
- Exchange
- OLED Nasdaq
- BBIO Nasdaq
- Market Cap
- OLED 7.2B
- BBIO 6.7B
- IPO Year
- OLED 1992
- BBIO 2019
- Fundamental
- Price
- OLED $143.35
- BBIO $34.71
- Analyst Decision
- OLED Strong Buy
- BBIO Strong Buy
- Analyst Count
- OLED 7
- BBIO 12
- Target Price
- OLED $190.43
- BBIO $57.09
- AVG Volume (30 Days)
- OLED 569.3K
- BBIO 2.9M
- Earning Date
- OLED 05-01-2025
- BBIO 04-29-2025
- Dividend Yield
- OLED 1.26%
- BBIO N/A
- EPS Growth
- OLED 4.58
- BBIO N/A
- EPS
- OLED 4.81
- BBIO N/A
- Revenue
- OLED $648,702,000.00
- BBIO $127,415,000.00
- Revenue This Year
- OLED $5.75
- BBIO $89.10
- Revenue Next Year
- OLED $10.76
- BBIO $57.07
- P/E Ratio
- OLED $29.80
- BBIO N/A
- Revenue Growth
- OLED 6.13
- BBIO N/A
- 52 Week Low
- OLED $103.70
- BBIO $21.62
- 52 Week High
- OLED $237.00
- BBIO $39.54
- Technical
- Relative Strength Index (RSI)
- OLED 50.81
- BBIO 50.58
- Support Level
- OLED $139.00
- BBIO $31.77
- Resistance Level
- OLED $148.36
- BBIO $33.93
- Average True Range (ATR)
- OLED 3.86
- BBIO 1.28
- MACD
- OLED -1.23
- BBIO -0.09
- Stochastic Oscillator
- OLED 23.42
- BBIO 57.14
About OLED Universal Display Corporation
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.